DEVELOPMENT OF HEPATITIS C VIRUS-LIKE PARTICLES AS CANDIDATE HCV VACCINE

开发丙型肝炎病毒样颗粒作为候选 HCV 疫苗

• 批准号: 7349750
• 负责人: KRISHNA H MURTHY
• 金额: $ 6.57万
• 依托单位: TEXAS BIOMEDICAL RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-05-01 至 2007-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7349750
• 关键词: DEVELOPMENT; HEPATITIS; VIRUS; LIKE; PARTICLES

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. At the present time, no vaccines to prevent infection with HCV are available and the epidemic continues unabated worldwide. The objectives of this study are to develop a candidate HCV vaccine consisting of HCV-like particles and to evaluate the immunogenicity of the vaccine in the chimpanzee model. HCV subtypes 1b and 1a are being titrate in four chimpanzees to provide a standardized inoculum for vaccine challenge dose. Of the three animals inoculated with subtype 1b, one has resisted infection, and the remaining two have developed chronic infections. T cell responses in all three animals are being evaluated to understand the difference in the outcome of the infection and to delineate the role of T cells in protective immunity against HCV infection. The remaining animal has been inoculated with subtype 1a and is being monitored for evidence of infection. Two chronically infected animals are being utilized to determine whether a pool of human monoclonal anti-HCV antibodies is capable of clearing chronic infection. The animals were treated with 5 mg/kg dose of the antibody preparation and their virological and immunological status are being monitored. An additional four HCV na¿ve chimpanzees were immunized with HCV-VLP vaccine formulated with adjuvants and immunostimulatory complexes. The vaccinated animals have been challenged with infectious HCV to determine the efficacy of the vaccine preventing infection.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子弹和调查员（PI）可能已经从其他NIH来源获得了主要资金，因此可以在其他清晰的条目中代表。列出的机构是针对该中心的，这不是调查人员的机构。目前，尚无防止HCV感染的疫苗，并且该流行病继续在全球范围内继续进行。这项研究的目的是开发由HCV样颗粒组成的候选HCV疫苗，并评估黑猩猩模型中疫苗的免疫原性。 HCV亚型1B和1A在四个黑猩猩中被尖端延伸，以提供标准化的接种疫苗挑战剂量的接种物。在接种亚型1B的三只动物中，一只抗性感染，其余两只患有慢性感染。正在评估所有三只动物的T细胞反应，以了解感染结果的差异，并描述T细胞在保护性免疫抗HCV感染中的作用。其余动物已接种亚型1a，并正在监测以获取感染的证据。两种慢性感染动物被用于确定人类单克隆抗HCV抗体是否能够清除慢性感染。用5 mg/kg的抗体制备治疗动物，并监测其病毒学和免疫学状态。另外四个HCVNA¿接种疫苗的动物受到感染性HCV的挑战，以确定预防感染的疫苗的效率。